Trade Summary

2 days ago, Seth Alpna, serving as Dir at Keros Therapeutics, Inc. (KROS), sold 2,625 shares at $10.72 per share, for a total transaction value of $28,140.00. Following this transaction, Seth Alpna now holds 9,767 shares of KROS.

This sale represents a 21.18% decrease in Seth Alpna's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, June 4, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 5, 2026 at 4:15 PM ET, 1 day after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.